VHA Covers Leqembi for Early Alzheimer’s

The Veterans Health Administration has decided to cover Eisai’s Leqembi (lecanemab-irmb) for treatment of veterans with early stages of Alzheimer’s disease.

Leqembi was granted Accelerated Approval in January and manufacturer Eisai is now seeking full FDA approval.

So far, HHS has restricted coverage of Leqembi to treatment administered in a clinical trial. However, the department has said it is open to revising its decision concerning expanded coverage of the drug.